Programmed death protein 1 inhibitors making inroads in multiple cancers.
作者信息
Brower Vicki
出版信息
J Natl Cancer Inst. 2015 May 9;107(5). doi: 10.1093/jnci/djv141. Print 2015 May.
PMID:25957444
Abstract
摘要
相似文献
1
Programmed death protein 1 inhibitors making inroads in multiple cancers.
J Natl Cancer Inst. 2015 May 9;107(5). doi: 10.1093/jnci/djv141. Print 2015 May.
2
Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Expert Rev Anticancer Ther. 2015;15(9):981-93. doi: 10.1586/14737140.2015.1074862. Epub 2015 Jul 30.
3
Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors.
Clin Adv Hematol Oncol. 2014 Nov;12(11):782-4.
4
PD-1 Blockers.
Cell. 2015 Aug 27;162(5):937. doi: 10.1016/j.cell.2015.07.045.
5
PD-1 inhibitor approved for melanoma.
Cancer Discov. 2014 Nov;4(11):1249. doi: 10.1158/2159-8290.CD-NB2014-144. Epub 2014 Sep 25.
6
American Association of Cancer Research Showcases Immunotherapy Advances.
J Natl Cancer Inst. 2015 Aug 4;107(8). doi: 10.1093/jnci/djv231. Print 2015 Aug.
7
Pembrolizumab for the treatment of melanoma.
Expert Rev Clin Pharmacol. 2015;8(5):515-27. doi: 10.1586/17512433.2015.1061430. Epub 2015 Jul 9.
8
Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1247-53. doi: 10.1080/17425255.2016.1216976. Epub 2016 Aug 16.
9
Beyond ipilimumab: new approaches target the immunological synapse.
J Natl Cancer Inst. 2011 Jul 20;103(14):1079-82. doi: 10.1093/jnci/djr281. Epub 2011 Jul 7.
10
PD-1 inhibitor becomes "breakthrough therapy".
Cancer Discov. 2013 Jul;3(7):OF14. doi: 10.1158/2159-8290.CD-NB2013-074. Epub 2013 May 16.
引用本文的文献
1
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.
Signal Transduct Target Ther. 2022 Sep 19;7(1):331. doi: 10.1038/s41392-022-01136-2.
Zotero 插件